Skip to Content

Abciximab Injection

Last Updated: June 20, 2018
Status: Current

Products Affected - Description
    • Reopro intravenous injection, Janssen, 2 mg/mL, 5 mL vial, 1 count, NDC 57894-0200-01
Reason for the Shortage
    • Janssen has Reopro on shortage due to a production interruption at their third party manufacturing site. The contract manufacturer cannot guarantee supply continuity in 2018 and beyond.
    • There are no other suppliers of abciximab.
Available Products
    • There are no presentations available

Estimated Resupply Dates

    • Janssen has Reopro on long-term back order and the company cannot estimate a release date.


Updated June 20, 2018 by Leslie Jensen, PharmD, Drug Information Specialist. Created April 16, 2018 by Megan Dryer, PharmD. Copyright 2018, Drug Information Service, University of Utah, Salt Lake City, UT.